SK3652003A3 - Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers - Google Patents

Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers Download PDF

Info

Publication number
SK3652003A3
SK3652003A3 SK365-2003A SK3652003A SK3652003A3 SK 3652003 A3 SK3652003 A3 SK 3652003A3 SK 3652003 A SK3652003 A SK 3652003A SK 3652003 A3 SK3652003 A3 SK 3652003A3
Authority
SK
Slovakia
Prior art keywords
bcl
cancer
dose
antisense oligonucleotide
administration
Prior art date
Application number
SK365-2003A
Other languages
English (en)
Slovak (sk)
Inventor
Raymond P Warrel Jr
Robert E Klem
Howard Fingert
Original Assignee
Genta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27397795&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK3652003(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genta Inc filed Critical Genta Inc
Publication of SK3652003A3 publication Critical patent/SK3652003A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SK365-2003A 2000-08-25 2001-08-23 Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers SK3652003A3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22797000P 2000-08-25 2000-08-25
US23700900P 2000-09-29 2000-09-29
US09/709,170 US7795232B1 (en) 2000-08-25 2000-11-10 Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
PCT/US2001/026414 WO2002017852A2 (en) 2000-08-25 2001-08-23 Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers

Publications (1)

Publication Number Publication Date
SK3652003A3 true SK3652003A3 (en) 2003-08-05

Family

ID=27397795

Family Applications (1)

Application Number Title Priority Date Filing Date
SK365-2003A SK3652003A3 (en) 2000-08-25 2001-08-23 Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers

Country Status (33)

Country Link
US (2) US7795232B1 (de)
EP (2) EP1313514B1 (de)
JP (1) JP2004507480A (de)
KR (1) KR20030034153A (de)
CN (1) CN1471408A (de)
AP (1) AP2003002761A0 (de)
AT (1) ATE432717T1 (de)
AU (2) AU8837301A (de)
BG (1) BG107641A (de)
BR (1) BR0113447A (de)
CA (1) CA2419480A1 (de)
CY (1) CY1109340T1 (de)
CZ (1) CZ301582B6 (de)
DE (1) DE60138892D1 (de)
DK (1) DK1313514T3 (de)
DZ (1) DZ3471A1 (de)
EA (1) EA005424B1 (de)
EE (1) EE200300074A (de)
ES (1) ES2327904T3 (de)
GE (1) GEP20063934B (de)
HK (1) HK1056505A1 (de)
HR (1) HRP20030102A2 (de)
HU (1) HUP0303125A2 (de)
IL (1) IL154409A0 (de)
MX (1) MXPA03001575A (de)
NO (1) NO20030858L (de)
OA (1) OA12586A (de)
PL (1) PL363050A1 (de)
PT (1) PT1313514E (de)
SK (1) SK3652003A3 (de)
UA (1) UA77945C2 (de)
WO (1) WO2002017852A2 (de)
YU (1) YU13603A (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5855911A (en) 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
US7309692B1 (en) 1996-07-08 2007-12-18 Board Of Regents, The University Of Texas System Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1
US6977244B2 (en) 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7704962B1 (en) 1997-10-03 2010-04-27 Board Of Regents, The University Of Texas System Small oligonucleotides with anti-tumor activity
DK2799555T3 (en) 2002-03-13 2017-05-22 Genomic Health Inc Gene Expression Profiling in Tumor Tissue Biopsies
AU2003295561A1 (en) * 2002-11-14 2004-06-15 Genta Salus Llc Inhibitory oliogonucleotides targeted to bcl-2
WO2004046386A1 (en) 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
DE10258677A1 (de) * 2002-12-13 2004-06-24 Elez, Vera, Dr. Kombinations-antisense-Oligonukleotid-Krebstherapie
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
DK1597391T3 (da) 2003-02-20 2009-01-12 Genomic Health Inc Anvendelse af intron-RNA til måling af genekspression
KR20060013426A (ko) 2003-05-30 2006-02-09 니뽄 신야쿠 가부시키가이샤 Ｂｃｌ-2의 발현을 억제하는 올리고 이중쇄 ＲＮＡ와그것을 함유하는 의약 조성물
DK1641810T4 (en) 2003-06-24 2017-07-03 Genomic Health Inc Predicting the likelihood of cancer recurrence
ES2905579T3 (es) 2003-07-10 2022-04-11 Genomic Health Inc Algoritmo del perfil de expresión y prueba para el pronóstico de la recaída del cáncer de mama
US20050196782A1 (en) 2003-12-23 2005-09-08 Kiefer Michael C. Universal amplification of fragmented RNA
GB0406415D0 (en) * 2004-03-22 2004-04-21 Inst Of Cancer Res The Materials and methods for treatment of cancer
CA2563074C (en) 2004-04-09 2014-05-20 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
US8815599B2 (en) 2004-06-01 2014-08-26 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
AU2013203202B2 (en) * 2004-08-26 2017-02-16 Engeneic Molecular Delivery Pty Ltd Delivering functional nucleic acids to mammalian cells via bacterially derived intact minicells
NZ553910A (en) 2004-08-26 2009-05-31 Engeneic Molecular Delivery Pty Delivering functional nucleic acids to mammalian cells via bacterially derived, intact minicells
US7930104B2 (en) 2004-11-05 2011-04-19 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
EP1815014B1 (de) 2004-11-05 2012-03-21 Genomic Health, Inc. Molekulare indikatoren für brustkrebsprognose und vorhersage des ansprechens auf eine behandlung
PL1957044T3 (pl) 2005-12-01 2013-11-29 Pronai Therapeutics Inc Amfoteryczny preparat liposomowy
TWI403320B (zh) 2005-12-16 2013-08-01 Infinity Discovery Inc 用於抑制ｂｃｌ蛋白和結合夥伴間之交互作用的化合物及方法
CN100368424C (zh) * 2006-07-21 2008-02-13 福建金山生物制药股份有限公司 抑制肿瘤的反义核苷酸
US20080171718A1 (en) * 2006-11-08 2008-07-17 Brown Bob D Methods and Compositions for Treating Cancer Using BCL-2 Antisense Oligomers, Tyrosine Kinase Inhibitors, and Chemotherapeutic Agents
DE102007020554A1 (de) * 2007-04-27 2008-10-30 Henkel Ag & Co. Kgaa Nukleinsäurehaltige kosmetische und/oder pharmazeutische Zubereitungen zur Behandlung epithelialen Deckgewebes
US20090098118A1 (en) 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
WO2009071681A2 (en) * 2007-12-07 2009-06-11 Santaris Pharma A/S Rna antagonist compounds for the modulation of bcl-2
CA2744031A1 (en) * 2008-11-21 2010-05-27 Isis Pharmaceuticals, Inc. Anticancer combination comprising docetaxel and an antisense oligonucleotide
WO2011012713A1 (en) 2009-07-30 2011-02-03 Antisense Pharma Gmbh Combination of a chemotherapeutic agent and an inhibitor of the tgf-beta system
KR101853509B1 (ko) * 2010-01-06 2018-04-30 큐알엔에이, 인크. 췌장 발달 유전자에 대한 천연 안티센스 전사체의 억제에 의한 췌장 발달 유전자와 관련된 질환의 치료
CN113607945A (zh) * 2015-07-07 2021-11-05 豪夫迈·罗氏有限公司 抗HER2抗体-药物缀合物和Bcl-2抑制剂的组合疗法
ES2965461T3 (es) 2015-08-03 2024-04-15 Biokine Therapeutics Ltd Inhibidor de CXCR4 para el tratamiento del cáncer
WO2021231486A1 (en) * 2020-05-13 2021-11-18 Unity Biotechnology, Inc. Cancer treatment by senescence induction followed by a senolytic

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015568A (en) 1986-07-09 1991-05-14 The Wistar Institute Diagnostic methods for detecting lymphomas in humans
US5202429A (en) 1986-07-09 1993-04-13 The Wistar Institute DNA molecules having human BCL-2 gene sequences
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5098890A (en) 1988-11-07 1992-03-24 Temple University-Of The Commonwealth System Of Higher Education Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
US5734033A (en) 1988-12-22 1998-03-31 The Trustees Of The University Of Pennsylvania Antisense oligonucleotides inhibiting human bcl-2 gene expression
US5831066A (en) 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
CA2025907A1 (en) 1989-09-21 1991-03-22 Franklin D. Collins Method of transporting compositions across the blood brain barrier
EP0633934A1 (de) 1992-04-02 1995-01-18 Imperial Cancer Research Technology Limited Modifizierte Zellen und Behandlungsverfahren
EP0668782B1 (de) 1992-10-21 2001-04-11 Temple University - Of The Commonwealth System Of Higher Education Die kombination von antineoplastischen mitteln und antisense-oligonukleotiden bei der behandlung von krebs
US5550019A (en) 1993-05-26 1996-08-27 La Jolla Cancer Research Foundation Methods of identifying compounds which alter apoptosis
US5783683A (en) * 1995-01-10 1998-07-21 Genta Inc. Antisense oligonucleotides which reduce expression of the FGFRI gene
US6214986B1 (en) * 1998-10-07 2001-04-10 Isis Pharmaceuticals, Inc. Antisense modulation of bcl-x expression

Also Published As

Publication number Publication date
ATE432717T1 (de) 2009-06-15
UA77945C2 (en) 2007-02-15
AP2003002761A0 (en) 2003-06-30
YU13603A (sh) 2006-05-25
IL154409A0 (en) 2003-09-17
EP1313514A4 (de) 2005-07-13
EP1313514A2 (de) 2003-05-28
BG107641A (bg) 2004-01-30
EP2135623A1 (de) 2009-12-23
JP2004507480A (ja) 2004-03-11
AU8837301A (en) 2002-03-13
EA005424B1 (ru) 2005-02-24
EE200300074A (et) 2004-12-15
DE60138892D1 (de) 2009-07-16
WO2002017852A2 (en) 2002-03-07
US7795232B1 (en) 2010-09-14
EA200300294A1 (ru) 2003-08-28
AU2001288373B2 (en) 2006-05-11
CZ301582B6 (cs) 2010-04-21
EP1313514B1 (de) 2009-06-03
HRP20030102A2 (en) 2005-04-30
CN1471408A (zh) 2004-01-28
CA2419480A1 (en) 2002-03-07
OA12586A (en) 2006-06-07
BR0113447A (pt) 2003-07-08
PT1313514E (pt) 2009-09-01
KR20030034153A (ko) 2003-05-01
GEP20063934B (en) 2006-10-10
CY1109340T1 (el) 2014-07-02
HUP0303125A2 (hu) 2003-12-29
NO20030858D0 (no) 2003-02-24
MXPA03001575A (es) 2004-11-01
US20100216867A1 (en) 2010-08-26
CZ2003848A3 (cs) 2003-11-12
NO20030858L (no) 2003-04-24
WO2002017852A3 (en) 2003-04-03
HK1056505A1 (en) 2004-02-20
DZ3471A1 (fr) 2002-03-07
ES2327904T3 (es) 2009-11-05
PL363050A1 (en) 2004-11-15
DK1313514T3 (da) 2009-10-12

Similar Documents

Publication Publication Date Title
EP1313514B1 (de) Methode zur behandlung einer bcl-2 störung unter verwendung von bcl-2 antisense oligomeren
AU2001288373A1 (en) Methods of treatment of a BCL-2 disorder using BCL-2 antisense oligomers
KR101697396B1 (ko) 결합 조직 성장 인자（ctgf）를 표적으로 하는 안티센스 화합물을 사용하여 켈로이드 또는 비후성 흉터를 치료하는 방법
TWI761305B (zh) 抑制Ｈｉｆ２α基因表現之組合物及方法
KR20130137725A (ko) 5-아자-시토신이 내부에 삽입된 올리고뉴클레오티드 유사체
JP7003044B2 (ja) Ａｎｇｐｔ２およびｐｄｇｆｂを標的化するｒｎａ複合体を用いる血管新生関連疾患の処置
JP2015518710A (ja) ヘモグロビン遺伝子ファミリー発現を調節するための組成物及び方法
US20040147473A1 (en) Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
KR20180104075A (ko) IL4Rα, TRPA1, 또는 F2RL1을 표적화하는 RNA 복합체를 사용한 아토피 피부염 및 천식의 치료
WO1997011170A1 (en) Antisense oligonucleotide chemotherapy for benign hyperplasia or cancer of the prostate
WO2004056971A2 (en) Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
US7662792B2 (en) Modulation of Fas and FasL expression
JP6437930B2 (ja) 悪性胸膜中皮腫を治療するためのマイクロｒｎａを基にしたアプローチ
US7855183B2 (en) Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
WO2016071431A9 (en) A combination for cancer therapy
WO1998013072A1 (en) Compositions for and methods of treating multiple drug resistance
ZA200301161B (en) Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers.
EP1313853B1 (de) Modulierung der fas und fasl expression durch ein synthetisches oligonukleotid und einen anti-fas antikörper
ES2383671T3 (es) Modulación de la expresión de Fas y FasL por un oligonucleótido-fosfodiéster sintético y un anticuerpo anti-Fas
WO2011009082A2 (en) Compositions comprising human rhbdf1-modulating nucleic acids and methods of use
EA041697B1 (ru) Композиции и способы для ингибирования экспрессии генов hif2альфа
WO2012018594A2 (en) Plant-derived polysaccharides for delivery of rna-based therapies

Legal Events

Date Code Title Description
FD9A Suspended procedure due to non-payment of fee